Rozner, R. N., Freites-Martinez, A., Shapiro, J., Geer, E. B., Goldfarb, S., & Lacouture, M. (2018). Safety of 5α-reductase inhibitors and spironolactone in breast cancer patients receiving endocrine therapies. Breast Cancer Res Treat.
Styl ChicagoRozner, Raquel N., Azael Freites-Martinez, Jerry Shapiro, Eliza B. Geer, Shari Goldfarb, a Mario Lacouture. "Safety of 5α-reductase Inhibitors and Spironolactone in Breast Cancer Patients Receiving Endocrine Therapies." Breast Cancer Res Treat 2018.
Citace podle MLARozner, Raquel N., et al. "Safety of 5α-reductase Inhibitors and Spironolactone in Breast Cancer Patients Receiving Endocrine Therapies." Breast Cancer Res Treat 2018.
Upozornění: Tyto citace jsou generovány automaticky. Nemusí být zcela správně podle citačních pravidel..